San Diego – August 7, 2012 (tentative) – MEI Pharma, Inc. (Nasdaq: MEIP), an oncology
company focused on the clinical development of novel therapies for the treatment of cancer,
announced today that they have entered into a definitive asset purchase agreement with S*BIO
Pte Ltd, a privately held biotechnology company, pursuant to which MEI Pharma will acquire
worldwide rights to Pracinostat, a potential best-in-class oral histone deacetylase (HDAC)
inhibitor.

Tidal energy developer Meygen has lodged plans for the first phase of a 400 megawatt project
in the Inner Sounds of the Pentland Firth.

Singapore’s Bio*One Capital Eyes Services, Data and Devices In Investment Push

Hand, Foot and Mouth Disease (HFMD) is
caused by enteroviral pathogens such as
enterovirus 71 (EV71). Although this is
generally a self-limiting disease characterised
by fever, mouth ulcers, and a rash, HFMD
caused by EV71 can lead to viral meningoencephalitis, myocarditis or poliomyelitis-like
paralysis, and may be fatal.

Atlantis Resources Corporation received an Achievement of Excellence award in the Small &
Medium Enterprise Category at the 2012 Singapore Business Federation awards dinner
ceremony held at the Marine Bay Sands Conference Centre. The award was presented by the
guest of honor, the Honorable Minister Mr. S. Iswaran (Minister, Prime Minister’s Office &
Second Minister for Home Affairs & Trade and Industry) and Singapore Business Federation
CEO, Mr. Ho Meng Kit. The award was received by Timothy Cornelius, CEO of Atlantis
Resources Corporation.

EMERYVILLE, CALIF., June 4, 2012 – Adamas Pharmaceuticals, Inc., a privately held
company, announced today that it will present an update on its NurelinTM (amantadine HCl
extended release capsules) program at the Cambridge Healthtech Institute’s (CHI) Targeting
Parkinson’s Disease Symposium being held today in Philadelphia

A strategic investor based in Singapore investing in globally
competitive businesses in Smart Energy and Efficiency as well
as Sustainable Environment.

EMERYVILLE, CALIF., May 15, 2012 – Adamas Pharmaceuticals, Inc., a privately held
company, announced today that it has held an End-of-Phase 2 meeting with the FDA to discuss
the proposed safety and efficacy studies to be conducted for the registration of Arimenda
(memantine HCl extended release and donepezil HCl) capsules. Arimenda, a once-daily fixed
dose combination of extended release memantine and donepezil, is being developed for the
treatment of moderate-to-severe Alzheimer’s dementia.

Cell Therapeutics Enters into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3
Candidate for Myelofibrosis

SAN DIEGO – April 18, 2012 – Sotera Wireless, Inc. announced that it has
received 510(k) clearance from the United States Food and Drug Administration
(FDA) for the ViSi MobileTM System, a new continuous vital signs monitoring
system for use in hospitals.